Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
Chronic Myeloid Leukemia News
CHRONIC MYELOID LEUKEMIA ADVISOR
Chronic Myeloid Leukemia News
Second-Generation TKIs in Advanced CML: 7-Year Survival Rates
In patients who have been newly diagnosed with AP-CML, the initiation of TKI2 therapies in the frontline setting provided excellent responses and survival rates.
Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
Although the study suggested the efficacy of the branded version was superior to its generic counterpart, more research may be necessary to tease out manufacturer differences.
Prototype Intervention Increased Adherence to TKIs in CML
A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.
Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.
New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.
Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs
Increased costs were found to be a result of more infections.
Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
Time of Response to TKI Therapies May Influence Patient Outcomes in CML
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML
Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.
Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.
Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.
Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia
Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.
Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia
Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.
Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia
Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.
FDA Approves Nilotinib for Pediatric Patients With CML
Patients one year or older are now eligible to receive the drug.
Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells
A recent study sought to determine the effect of ivermectin against CML cells, whether ivermectin can sensitize cells to BCR-ABL TKIs, and its mechanism of action.
Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML
A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.
Want to read more?
Please login or register first to view this content.
